Sucampo Pharma (SCMP) Tops Q2 EPS by 6c; Boosts FY15 EPS Outlook

Sucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.21, $0.06 better than the analyst estimate of $0.15. Revenue for the quarter came in at $34.9 million versus the consensus estimate of $31.9 million.

Sucampo Pharma sees FY2015 EPS of $0.65-$0.75, versus the consensus of $0.62.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Pentair (PNR) Tops Q1 EPS by 4c, Misses on Revenue; Offers FY24 EPS Guidance
• Kimberly-Clark (KMB) Tops Q1 EPS by 38c; updates outlook